Login / Signup

Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.

John P HaranJose C PineroYan ZhengNorma Alonzo PalmaMark Wingertzahn
Published in: Trials (2021)
The full protocols are attached as additional files (Additional files 1 and 2), accessible from the ClinicalTrials.gov website. In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocols. The study protocols have been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional files 3 and 4).
Keyphrases
  • open label
  • coronavirus disease
  • clinical practice
  • sars cov
  • randomized controlled trial
  • clinical trial
  • squamous cell carcinoma
  • study protocol
  • phase ii
  • double blind